M. A. Dimopoulos, P. Sonneveld, and N. Leung, International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment, J Clin Oncol, vol.34, pp.1544-1557, 2016.

E. Moumas, W. Hanf, and E. Desport, New insights in the treatment of myeloma with renal failure, Néphrol Thér, vol.7, pp.457-466, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00945697

M. A. Dimopoulos, E. Kastritis, and L. Rosinol, Pathogenesis and treatment of renal failure in multiple myeloma, Leukemia ao^ ut, vol.22, pp.1485-1493, 2008.

C. A. Hutchison, V. Batuman, and J. Behrens, The pathogenesis and diagnosis of acute kidney injury in multiple myeloma, Nat Rev Nephrol, vol.8, pp.43-51, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00696471

N. Leung, M. A. Gertz, and S. R. Zeldenrust, Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains, Kidney Int, vol.73, pp.1282-1288, 2008.

C. A. Hutchison, P. Cockwell, and S. Stringer, Early reduction of serum-free light chains associates with renal recovery in myeloma kidney, J Am Soc Nephrol, vol.22, pp.1129-1136, 2011.

C. A. Hutchison, N. Heyne, and P. Airia, Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis, Nephrol Dial Transplant, vol.27, pp.3823-3828, 2012.

C. A. Hutchison, Reduction of serum free light chains predict renal recovery, Ann Hematol, vol.89, pp.627-628, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00486564

H. U. Gerth, M. Pohlen, and . Gö-rlich-d, Impact of high-cut-off dialysis on renal recovery in dialysis-dependent multiple myeloma patients: results from a case-control study, PloS One, vol.11, p.154993, 2016.

S. Stringer, K. Basnayake, and C. Hutchison, Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney), Bone Marrow Res, vol.2011, p.493697, 2011.

W. F. Clark, A. K. Stewart, and G. A. Rock, Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial, Ann Intern Med, vol.143, pp.777-784, 2005.

C. A. Hutchison, P. Cockwell, and S. Reid, Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies, J Am Soc Nephrol, vol.18, pp.886-895, 2007.

C. A. Hutchison, A. R. Bradwell, and M. Cook, Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis, Clin J Am Soc Nephrol, vol.4, pp.745-754, 2009.

C. A. Hutchison, S. Harding, and G. Mead, Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care, Artif Organs, vol.32, pp.910-917, 2008.

B. L. Burnette, N. Leung, and S. V. Rajkumar, Renal improvement in myeloma with bortezomib plus plasma exchange, N Engl J Med, vol.364, pp.2365-2366, 2011.

F. Bridoux and J. Fermand, Optimizing treatment strategies in myeloma cast nephropathy: rationale for a randomized prospective trial, Adv Chronic Kidney Dis, vol.19, pp.333-341, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00945707

C. A. Hutchison and F. Bridoux, Renal impairment in multiple myeloma: time is of the essence, J Clin Oncol, vol.29, pp.312-313, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00945689

C. A. Hutchison, M. Cook, and N. Heyne, European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial, Trials, vol.9, p.55, 2008.

G. Cohen, M. Rudnicki, and S. Schmaldienst, Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients, Nephrol Dial Transplant, vol.17, pp.879-883, 2002.

D. Chaintreuil, A. Jolivot, and N. Rognant, Epuration des chaines légè res par membrane PMMA et ré cupé ration ré nale dans le myé lome multiple. Société francophone de né phrologie, dialyse et transplantation (SFNDT). Genè ve, Nephrol Ther, vol.8, pp.323-324, 2012.

M. Lino, F. Lavainne, and C. Garandeau, Hé modialyse intensive avec membrane de haut flux comme traitement de la tubulopathie myé lomateuse (Poster), 2008.

S. Kumar, B. Paiva, and K. C. Anderson, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, vol.17, pp.328-346, 2016.

A. S. Levey, J. P. Bosch, and J. B. Lewis, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group, Ann Intern Med, vol.130, pp.461-470, 1999.

A. S. Levey, T. Greene, and J. Kusek, A simplified equation to predict glomerular filtration rate from serum creatinine (abstract), J Am Soc Nephrol, vol.11, p.155, 2000.

B. Durie, J. Harousseau, and J. S. Miguel, International uniform response criteria for multiple myeloma, Leukemia, vol.20, pp.1467-1473, 2006.

N. O. Peters, E. Laurain, and J. Cridlig, Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study, Hemodial Int, vol.15, pp.538-545, 2011.

H. Hata, K. Nishi, and W. Oshihara, Adsorption of Bence-Jones protein to polymethylmethacrylate membrane in primary amyloidosis, Amyloid, vol.16, pp.108-110, 2009.

J. M. Campistol, J. V. Torregrosa, and E. Ponz, Beta-2-microglobulin removal by hemodialysis with polymethylmethacrylate membranes, Contrib Nephrol, vol.125, pp.76-85, 1999.

F. Bridoux, B. Pegourie, and K. Augeul-meunier, Treatment of myeloma cast nephropathy (MCN): a randomized trial comparing intensive haemodialysis (HD) with high cut-off (HCO) or standard high-flux dialyzer in patients receiving a Bortezomibbased regimen (the MYRE Study, by the Intergroupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT)). ASH, Blood, vol.128, p.978, 2016.